COMPANY
Myogenica
Myogenica’s co-founders are a combination of experts in muscle regeneration, stem cell biology and cell and gene therapy development. Myogenica was formed in 2022 as a spin out of the University of Minnesota to develop MyoPAXon, an induced pluripotent stem cell (iPSC) platform for muscle regeneration. From company website Source · Oct 13, 2026
Funding and NIH signals
- NIH award NIH awarded $701K (STTR Phase II 5R42AR083779-03, continuation, notice Jul 8, 2026). NIH RePORTER 5R42AR083779-03 (Jul 8, 2026)
Evidence (1 event)
- Jul 8, 2026 · NIH RePORTER 5R42AR083779-03
Organization: MYOGENICA INC.; City/State: SAINT PAUL, MN; Project number: 5R42AR083779-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 701471; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD; Organization type: Domestic For-Profits
- Jul 8, 2026 · NIH RePORTER 5R42AR083779-03